Anakuria Therapeutics

Anakuria Therapeutics, a subsidiary of Navitor Pharmaceuticals, aims to advance its novel selective rapamycin analog mTORC1 inhibitors. The mechanistic target of rapamycin complex 1 (mTORC1) controls the rate and capacity of cellular protein and other component synthesis. Increased mTORC1 activity contributes to various aging-related diseases by enhancing protein misfolding and driving cellular stress, inflammation, and fibrosis.